Featured Research

Towards An AIDS Vaccine: Unusual Antibody That Targets HIV Described By Scientists At TSRI

Date:

June 27, 2003

Source:

Scripps Research Institute

Summary:

A group of scientists from The Scripps Research Institute (TSRI) and several other institutions has solved the structure of an antibody that effectively neutralizes human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS).

Share This

A group of scientists from The Scripps Research Institute (TSRI) and several other institutions has solved the structure of an antibody that effectively neutralizes human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS).

Related Articles

The antibody binds to sugars on the surface of HIV and effectively neutralizes the virus because of its unique structure, which is described in the latest issue of the journal Science.

"What we found was an unusual configuration of the antibody in which its two Fab domains -- the antigen recognition units -- are 'interdigitating' with each other," says TSRI Professor Ian Wilson, D.Phil., one of two TSRI professors who led the research. "Nothing like this has ever been seen before."

This new structure is an important step toward the goal of designing an effective vaccine against HIV, and it gives the researchers a new way to design antibodies in general.

"It may enable us to make antibodies that recognize whole new sets of molecules," says TSRI Professor Dennis Burton, Ph.D., the other TSRI professor who led the research.

The Problem of HIV and Antibodies

HIV causes AIDS by binding to, entering and ultimately, killing T helper cells, immune cells that are necessary to fight off infections by common bacteria and other pathogens. As HIV depletes the body of T helper cells, common pathogens can become potentially lethal.

The latest statistics are grim. The World Health Organization estimates that around 40 million people are living with HIV worldwide. During 2001 alone, more than four million men, women, and children succumbed to the disease, and by the end of that year, the disease had made orphans of 14 million children. In the United States, 40,000 people are infected with HIV each year.

One of the most compelling medical challenges today is to develop a vaccine that will provide complete prophylactic protection to someone who is later exposed to this virus. An important part of such a vaccine will be a component that elicits or induces effective neutralizing antibodies against HIV in the blood of the vaccinated person.

Also called immunoglobins, antibodies are the basis for many existing vaccines, including those against measles, polio, hepatitis B, and hepatitis A. HIV antibodies are produced by the body's B cells after HIV enters the bloodstream. During such an immune response, the antibodies circulate through the blood. Good antibodies bind to and "neutralize" the virus, making it unable to invade cells. Because neutralizing antibodies attack the virus before it enters cells, they could conceivably be used to prevent HIV infection if they were present prior to virus exposure. A vaccine would seek to elicit these neutralizing antibodies.

This is easier said than done. The body makes lots of antibodies against HIV, but they are almost always unable to neutralize the virus. Much of the viral surface is coated with carbohydrates (sugars), which are hard for the immune system to attack because these sugars are made by human cells and attached by human proteins. In other words, they are "self" and should not be recognized by antibodies.

However, in rare instances some people have produced antibodies that broadly neutralize HIV. One such antibody, called 2G12, was isolated from an HIV-positive individual about a decade ago by Hermann Katinger, a doctor at the Institute for Applied Microbiology of the University of Agriculture in Vienna, Austria and one of the authors on the paper. This antibody is not like ordinary antibodies.

"The Fab [antigen recognition] arms are interlocked," says Burton. "That is a unique arrangement, and it is good for recognizing a cluster of shapes like sugars on a virus."

The 2G12 antibody forms an unusual "dimer" interface where two antibodies create an unusual multivalent binding interface with multiple binding sites that recognizes an unusual arrangement of 2-3 "oligomannose" sugars on the surface of protein spikes called gp120 that decorate the coat of HIV. This allows the antibody to properly target HIV virions as foreign pathogens. The sugars are human but their arrangement is foreign-and it is this arrangement that the antibodies recognize.

These results are a step in the direction of designing an effective AIDS vaccine because it reveals what these neutralizing antibodies should look like. The next step is to use the structure of the antibody as a template to design an "antigen" that would stimulate the human immune system to make 2G12 or similar broadly neutralizing antibodies against HIV.

The results are also important because the structure of the antibody is something that has never been seen before. "Can we now," asks Wilson, "use this [knowledge] to engineer antibodies with higher affinity against other antigens or clusters of antigens?"

###

The TSRI study combined experts from several institutions besides TSRI, including Pauline M. Rudd, Ph.D., and Raymond A. Dwek, D.Phil., D.Sc., FRS, from the Glycobiology Institute at Oxford University in the United Kingdom. Also involved in the study were researchers in the Department of Biological Science and Structural Biology at Florida State University in Tallahassee.

The research was supported by The Skaggs Institute for Research, which funds The Skaggs Institute for Chemical Biology at TSRI. TSRI is one of the world's largest, private, non-profit biomedical research organizations and is internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune diseases, cardiovascular diseases and synthetic vaccine development. It is dedicated to the creation of basic knowledge in the biosciences for medical application and the betterment of human health, to the pursuit of fundamental scientific advances through interdisciplinary programs and collaborations, and to the education and training of researchers from around the world preparing to meet the scientific challenges of the future.

Grants from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of General Medical Sciences (NIGMS) also supported this research. NIGMS is part of the National Institutes of Health (NIH), U.S. Department of Health and Human Services and supports basic biomedical research that lays the foundation for advances in disease diagnosis, treatment, and prevention. NIGMS also trains tomorrow's scientists and makes special efforts to increase the number of minority researchers. A component of the NIH, NIAID conducts and supports research that strives to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten hundreds of millions of people worldwide. NIAID's mission is driven by a strong commitment to basic research and the understanding that the fields of immunology, microbiology, and infectious disease are related and complementary.

The research is further supported by the International AIDS Vaccine Initiative (IAVI). Burton and Wilson are part of the multi-million-dollar Neutralizing Antibody Consortium launched last year by IAVI, a global nonprofit organization working to speed scientific progress toward developing safe and effective vaccines to prevent HIV/AIDS that will be accessible worldwide. IAVI's work focuses on four areas: mobilizing support through advocacy and education, accelerating scientific progress, encouraging industrial participation in AIDS vaccine development, and assuring global access. Burton is the director of the Neutralizing Antibody Consortium.

Scripps Research Institute. "Towards An AIDS Vaccine: Unusual Antibody That Targets HIV Described By Scientists At TSRI." ScienceDaily. ScienceDaily, 27 June 2003. <www.sciencedaily.com/releases/2003/06/030627000017.htm>.

Scripps Research Institute. (2003, June 27). Towards An AIDS Vaccine: Unusual Antibody That Targets HIV Described By Scientists At TSRI. ScienceDaily. Retrieved March 3, 2015 from www.sciencedaily.com/releases/2003/06/030627000017.htm

Scripps Research Institute. "Towards An AIDS Vaccine: Unusual Antibody That Targets HIV Described By Scientists At TSRI." ScienceDaily. www.sciencedaily.com/releases/2003/06/030627000017.htm (accessed March 3, 2015).

More From ScienceDaily

More Health & Medicine News

Featured Research

Mar. 3, 2015 — Adults over the age of 30 only catch flu about twice a decade, a new study suggests. So, while it may feel like more, flu-like illness can be caused by many pathogens, making it difficult to assess ... full story

Mar. 3, 2015 — No significant change in home habits of smokers have been observed in the aftermath of a ban on smoking in public spaces, researchers report. Greater inspiration to kick the habit likely comes from ... full story

Mar. 3, 2015 — Heart function has been associated with the development of dementia and Alzheimer's disease through a new study. Participants with decreased heart function, measured by cardiac index, were two to ... full story

Mar. 3, 2015 — Children of recently separated or divorced families are likelier to drink sugar-sweetened beverages than children in families where the parents are married, putting them at higher risk for obesity ... full story

Mar. 3, 2015 — Gastric bypass and similar stomach-shrinking surgeries are a popular option for obese patients looking to lose weight or treat type 2 diabetes. While the surgeries have been linked to a decreased ... full story

Mar. 3, 2015 — Most people consume more salt than they need and therefore have a higher risk of heart disease and stroke, which are the two leading causes of death worldwide. But a new study reveals that dietary ... full story

Mar. 3, 2015 — Twice as many children born to mothers who took antibiotics during pregnancy were diagnosed with asthma by age 3 than children born to mothers who didn’t take prenatal antibiotics, a new study has ... full story

Mar. 3, 2015 — Pediatric otolaryngologists and surgeons are concerned with parents getting the wrong message regarding the safety/desirability of letting babies and young children eat peanuts to prevent them from ... full story

Featured Videos

Mom Triumphs Over Tragedy, Helps Other Families

AP (Mar. 3, 2015) — After her son, Dax, died from a rare form of leukemia, Julie Locke decided to give back to the doctors at St. Jude Children&apos;s Research Hospital who tried to save his life. She raised $1.6M to help other patients and their families. (March 3)
Video provided by AP

Looted and Leaking, South Sudan's Oil Wells Pose Health Risk

AFP (Mar. 3, 2015) — Thick black puddles and a looted, leaking ruin are all that remain of the Thar Jath oil treatment facility, once a crucial part of South Sudan&apos;s mainstay industry. Duration: 01:13
Video provided by AFP

Woman Convicted of Poisoning Son

AP (Mar. 3, 2015) — A woman who blogged for years about her son&apos;s constant health woes was convicted Monday of poisoning him to death by force-feeding heavy concentrations of sodium through his stomach tube. (March 3)
Video provided by AP

Related Stories

Aug. 5, 2014 — Researchers are investigating antibodies to fight Ebola virus, including the three antibodies recently used to treat two American health care workers infected with the Ebola virus. Ebola virus causes ... full story

May 15, 2014 — A vaccine or other therapy directed at a single site on a surface protein of HIV could in principle neutralize nearly all strains of the virus—thanks to the diversity of targets the site presents ... full story

Oct. 31, 2013 — Two teams are reporting results from experiments in which they infused powerful anti-HIV antibodies into monkeys infected with an HIV-like virus, rapidly reducing the amount of virus, or viral load, ... full story

Sep. 20, 2013 — Researchers have discovered that an antibody that binds and neutralizes HIV likely also targets the body’s own “self” proteins. This finding could complicate the development of HIV vaccines ... full story

May 24, 2013 — Detection of HIV antibodies is used to diagnose HIV infection and monitor trials of experimental HIV/AIDS vaccines. New, more sensitive detection systems being developed use microspheres to capture ... full story

ScienceDaily features breaking news and videos about the latest discoveries in health, technology, the environment, and more -- from major news services and leading universities, scientific journals, and research organizations.